1079649-91-4Relevant academic research and scientific papers
FUSED PYRIMIDINE COMPOUNDS AS KCC2
-
Page/Page column 40-41, (2021/09/17)
The invention concerns compounds of Formula (I): (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KCC2 mediated diseases.
Discovery of P2X3 selective antagonists for the treatment of chronic pain
Cantin, Louis-David,Bayrakdarian, Malken,Buon, Christophe,Grazzini, Eric,Hu, Yun-Jin,Labrecque, Jean,Leung, Carmen,Luo, Xuehong,Martino, Giovanni,Paré, Michel,Payza, Kemal,Popovic, Nirvana,Projean, Denis,Santhakumar,Walpole, Christopher,Yu, Xiao Hong,Tomaszewski, Miros?aw J.
scheme or table, p. 2565 - 2571 (2012/05/05)
Purinergic receptor P2X3 has been linked to analgesia in a number of pre-clinical models of pain, and is expressed in the human pain perception pathway. Only few P2X3-selective antagonists have been reported to date. This Letter describes the SAR and in vivo analgesic profile of a novel scaffold of selective P2X3 antagonists.
PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
-
Page/Page column 110-111, (2009/01/20)
Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4, and R5 and are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
